(2016) Opioid Drugs in Patients With Liver Disease: A Systematic Review. Hepatitis Monthly. p. 12. ISSN 1735-143X
Text
Opioid Drugs in Patients With Liver DiseaseA Systematic Review.pdf Download (168kB) |
Abstract
Context: The liver, one of the most important organs of the body, is known to be responsible for several functions. The functional contribution of the liver to the metabolism of carbohydrates, protein, drugs and toxins, fats and cholesterol and many other biological processes are still unknown. Liver disorders are classified into two types: acute and chronic. Different drugs are used in liver diseases to treat and control pain. Most pain relief medications such as opioids are metabolized via the liver; therefore, the adverse reactions of drugs are probably higher for patients with liver disease. The current study aimed to evaluate the effects of opioid drugs on patients with liver disease; therefore, it is necessary to select suitable opioids for such patients. Evidence Acquisition: This review was written by referring to research literature including 70 articles and four textbooks published from 1958 to 2015 on various reputable sites. Searches were carried out on the key phrases of narcotic pain relievers (opioids), acute and chronic hepatic failure, opioid adverse drug reactions, drug-induced liver injury (DILI) and other similar keywords. References included a variety of research papers (descriptive and analytical), intervention and review articles. Results: In patients with liver disease, administration of opioid analgesics should be observed, accurately. As a general rule, lower doses of drugs should be administered at regular intervals based on the signs of drug accumulation. Secondly, the interactions of opioid drugs with different levels of substrates of the P450 cytochrome enzyme should be considered. Conclusions: Pain management in patients with liver dysfunction is always challenging to physicians because of the adverse reactions of drugs, especially opioids. Opioids should be used cautiously since they can cause sedation, constipation and sudden encephalopathy effects. Since the clearance of these drugs in patients with hepatic insufficiency is decreased, the initial dose must be decreased, the intervals between doses should be increased and some patients need to be continuously assessed.
Item Type: | Article |
---|---|
Keywords: | Opioids Liver Disease Adverse Drug Reactions alfentanil pharmacokinetics induced hepatotoxicity hepatic-failure renal-failure safe use morphine buprenorphine metabolism fentanyl pain Gastroenterology & Hepatology |
Divisions: | |
Page Range: | p. 12 |
Journal or Publication Title: | Hepatitis Monthly |
Journal Index: | ISI |
Volume: | 16 |
Number: | 4 |
Identification Number: | https://doi.org/10.5812/hepatmon.32636 |
ISSN: | 1735-143X |
Depositing User: | مهندس مهدی شریفی |
URI: | http://eprints.bmsu.ac.ir/id/eprint/5041 |
Actions (login required)
View Item |